Mark Cuban Proposes Doctor-Configured AI Assistants to Bridge Gaps Between Patient Visits

Billionaire investor Mark Cuban is advocating for a formal integration of commercial generative AI into medical care, suggesting that physicians should actively configure AI models to manage ongoing communication with patients between routine consultations.

Rather than leaving patients to independently consult chatbots for medical queries, Cuban outlines a model where clinicians directly customize foundational tools—such as OpenAI's ChatGPT, Anthropic's Claude, Google's Gemini, or xAI's Grok. Under this framework, practitioners would pre-program specific questions, medication reminders, and monitoring criteria tailored to an individual's treatment plan.

Automating the Inter-Visit Interval

Under Cuban’s proposed workflow, the AI agent would conduct regular check-ins to track daily habits, symptom progression, and treatment compliance. The system would synthesize this ongoing qualitative data into organized clinical briefs, giving healthcare providers richer context before a patient steps into an examination room.

The premise is explicitly framed around clinical augmentation rather than automated diagnosis. By delegating longitudinal data collection to software, proponents argue practitioners could spend less time on routine administrative intake and more time evaluating synthesized patient trends.

Regulatory and Practical Hurdles

While asynchronous monitoring has long been a goal of digital health platforms, deploying consumer large language models into clinical pathways presents significant friction. Healthcare systems face stringent compliance mandates under HIPAA, alongside unresolved liability questions surrounding model hallucinations or missed clinical red flags during automated check-ins. Additionally, physicians already burdened by electronic health record inbox fatigue may resist absorbing continuous feeds of AI-generated summaries without dedicated reimbursement codes.

Cuban, who co-founded the direct-to-consumer pharmacy venture Mark Cuban Cost Plus Drug Company, continues to target structural inefficiencies in healthcare delivery. His latest commentary reflects a broader push among technology investors seeking to convert general-purpose AI models into specialized operational tools for heavily regulated industries.